These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15016898)

  • 1. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
    Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
    J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR.
    Tosi G; Meazza R; De Lerma Barbaro A; D'Agostino A; Mazza S; Corradin G; Albini A; Noonan DM; Ferrini S; Accolla RS
    Eur J Immunol; 2000 Apr; 30(4):1120-6. PubMed ID: 10760801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides.
    Moreau E; Belliard G; Partidos CD; Pradezinsky F; Le Buanec H; Muller S; Desgranges C
    J Gen Virol; 2004 Oct; 85(Pt 10):2893-2901. PubMed ID: 15448351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody to HIV-1 Tat protein inhibits the replication of virus in culture.
    Steinaa L; Sørensen AM; Nielsen JO; Hansen JE
    Arch Virol; 1994; 139(3-4):263-71. PubMed ID: 7832634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tat-neutralizing antibodies in vaccinated macaques.
    Tikhonov I; Ruckwardt TJ; Hatfield GS; Pauza CD
    J Virol; 2003 Mar; 77(5):3157-66. PubMed ID: 12584340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies.
    Mhashilkar AM; LaVecchio J; Eberhardt B; Porter-Brooks J; Boisot S; Dove JH; Pumphrey C; Li X; Weissmahr RN; Ring DB; Ramstedt U; Marasco WA
    Hum Gene Ther; 1999 Jun; 10(9):1453-67. PubMed ID: 10395371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.
    Shang F; Huang H; Revesz K; Chen HC; Herz R; Pinter A
    J Virol; 1991 Sep; 65(9):4798-804. PubMed ID: 1714518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo.
    Re MC; Furlini G; Vignoli M; Ramazzotti E; Roderigo G; De Rosa V; Zauli G; Lolli S; Capitani S; La Placa M
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(4):408-16. PubMed ID: 7583436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lipidated anti-Tat antibody enters living cells and blocks HIV-1 viral replication.
    Cruikshank WW; Doctrow SR; Falvo MS; Huffman K; Maciaszek J; Viglianti G; Raina J; Kornfeld H; Malfroy B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Mar; 14(3):193-203. PubMed ID: 9117450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.
    Ruckwardt TJ; Tikhonov I; Berg S; Hatfield GS; Chandra A; Chandra P; Gilliam B; Redfield RR; Gallo RC; Pauza CD
    J Virol; 2004 Dec; 78(23):13190-6. PubMed ID: 15542671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A monoclonal antibody defines a novel HIV type 1 Tat domain involved in trans-cellular trans-activation.
    Valvatne H; Szilvay AM; Helland DE
    AIDS Res Hum Retroviruses; 1996 May; 12(7):611-9. PubMed ID: 8743086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and functional activity of isotype and subclass switched human monoclonal antibody reactive with the base of the V3 loop of HIV-1 gp120.
    Liu F; Bergami PL; Duval M; Kuhrt D; Posner M; Cavacini L
    AIDS Res Hum Retroviruses; 2003 Jul; 19(7):597-607. PubMed ID: 12908937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein.
    Rodman TC; To SE; Hashish H; Manchester K
    Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7719-23. PubMed ID: 7689227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of recombinant, library-derived antibody fragments against p24 for human immunodeficiency virus type 1 diagnostics.
    de Haard HJ; Kazemier B; Koolen MJ; Nijholt LJ; Meloen RH; van Gemen B; Hoogenboom HR; Arends JW
    Clin Diagn Lab Immunol; 1998 Sep; 5(5):636-44. PubMed ID: 9729530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody to HIV-1 Tat protein, a key molecule in HIV-1 pathogenesis. A brief review.
    Re MC; Gibellini D; Vitone F; La Placa M
    New Microbiol; 2001 Apr; 24(2):197-205. PubMed ID: 11346305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection.
    Richardson MW; Mirchandani J; Duong J; Grimaldo S; Kocieda V; Hendel H; Khalili K; Zagury JF; Rappaport J
    Biomed Pharmacother; 2003 Jan; 57(1):4-14. PubMed ID: 12642031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and virological effects of intracellular anti-Rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains.
    Duan L; Zhang H; Oakes JW; Bagasra O; Pomerantz RJ
    Hum Gene Ther; 1994 Nov; 5(11):1315-24. PubMed ID: 7893803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry.
    Daelemans D; Schols D; Witvrouw M; Pannecouque C; Hatse S; van Dooren S; Hamy F; Klimkait T; de Clercq E; VanDamme AM
    Mol Pharmacol; 2000 Jan; 57(1):116-24. PubMed ID: 10617686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.